HSDT (Helius Medical Technologies) Operating Income : $-13.86 Mil (TTM As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Helius Medical Technologies Operating Income?

Helius Medical Technologies's Operating Income for the three months ended in Dec. 2024 was $-3.11 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-13.86 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Helius Medical Technologies's Operating Income for the three months ended in Dec. 2024 was $-3.11 Mil. Helius Medical Technologies's Revenue for the three months ended in Dec. 2024 was $0.15 Mil. Therefore, Helius Medical Technologies's Operating Margin % for the quarter that ended in Dec. 2024 was -2,044.08%.

Warning Sign:

Helius Medical Technologies Inc operating margin has been in a 5-year decline. The average rate of decline per year is -4.5%.

Helius Medical Technologies's 5-Year average Growth Rate for Operating Margin % was -4.50% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Helius Medical Technologies's annualized ROC % for the quarter that ended in Dec. 2024 was -990.67%. Helius Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -8,425.76%.

Helius Medical Technologies Operating Income Historical Data

The historical data trend for Helius Medical Technologies's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helius Medical Technologies Operating Income Chart

Helius Medical Technologies Annual Data

Trend

Mar15

Mar16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Income

Get a 7-Day Free Trial

-14.39

-18.14

-14.76

-12.27

-13.86

Helius Medical Technologies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Operating Income	Get a 7-Day Free Trial															-2.25	-3.42	-3.27	-4.07	-3.11

Helius Medical Technologies Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.86 Mil.

Helius Medical Technologies (NAS:HSDT) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Helius Medical Technologies's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	-12.428 * ( 1 - 0% )	/	( (1.308	+	1.201)	/ 2 )
=	-12.428	/	1.2545
=	-990.67 %

where

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.585	-	0.809	-	( 3.468	-	max(0, 1.496	-	5.406	+	3.468	))
=	1.308

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.542	-	1.253	-	( 1.088	-	max(0, 2.163	-	3.424	+	1.088	))
=	1.201

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Helius Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2024		Q: Dec. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-12.428	/	( ( (0.177 + max(-0.034, 0))	+	(0.118 + max(-0.38, 0)) )	/	2 )
=	-12.428	/	( ( 0.177	+	0.118 )	/	2 )
=	-12.428	/	0.1475
=	-8,425.76 %

where Working Capital is:

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.025	+	1.108	+	0.306)	-	(0.809	+	0.042	+	0.622)
=	-0.034

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.07	+	1.091	+	0.61)	-	(1.253	+	0.039	+	0.859)
=	-0.38

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Helius Medical Technologies's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as:

Operating Margin %	=	Operating Income (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-3.107	/	0.152
	=	-2,044.08 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Helius Medical Technologies Operating Income Related Terms

Thank you for viewing the detailed overview of Helius Medical Technologies's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Helius Medical Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Helius Medical Technologies Inc (NAS:HSDT) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

642 Newtown Yardley Road, Suite 100, Newtown, PA, USA, 18940

Website

https://www.heliusmedical.com

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

Executives

Dane Andreeff	director, 10 percent owner, officer: President and CEO	C/O ANDREEFF EQUITY ADVISORS L.L.C., 140 E. ST. LUCIA LANE, SANTA ROSA BEACH FL 32459
Jeffrey S Mathiesen	director, officer: CFO and Treasurer	43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Favit-van Pelt Antonella R.	officer: Chief Medical Officer	C/O HELIUS MEDICAL TECHNOLOGIES, INC., 642 NEWTOWN YARDLEY ROAD, NEWTOWN PA 18940
Paul Buckman	director	12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Sherrie L Perkins	director	5033 TANGLE LANE, HOUSTON TX 77056
Jennifer Laux	officer: Chief Commercial Officer	642 NEWTOWN YARDLEY ROAD, SUITE 100, NEWTOWN PA 18940
Thomas E Griffin	director	C/O ENTELLUS MEDICAL, INC., 3600 HOLLY LANE NORTH, SUITE 40, PLYMOUTH MN 55447
Blane Walter	director	500 OLDE WORTHINGTON ROAD, WESTERVILLE OH 43082
Edward M Straw	director	C/O ESTEE LAUDER COMPANIES, 767 FIFTH AVENUE, NEW YORK NY 10153
Joyce N Laviscount	officer: See Remarks	100 ENDO BOULEVARD, CHADDS FORD PA 19317
Huaizheng Peng	director	HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Philippe Deschamps	director, 10 percent owner, officer: President & CEO	105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Mitch E Tyler	director	HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Jonathan Sackier	10 percent owner, officer: Chief Medical Officer	HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
A&b (hk) Co Ltd	10 percent owner	8/F BLDG A TONGFANG INFORMATION HARBOR, NO 11 LANGSHAN ROAD NANSHAN DISTRICT, SHENZHEN F4 518057